BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Bioreason Inc. Extends Collaboration With FDA


10/19/2005 5:09:30 PM

SANTA FE, N.M., Dec. 10 /PRNewswire/ -- Bioreason, Inc., a leading supplier of software solutions for rapid, in-depth analysis of drug discovery screening and optimization data, announced today the extension of its Material Transfer Agreement (MTA) with the U.S. Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER) for a period of one year. Under the agreement, the FDA will have limited access to the ClassPharmer technology in exchange for the use of certain toxicity data. In addition, the long-term objectives described in the agreement include the collaborative development of a human toxicology prediction solution that incorporates non-proprietary FDA data and predictive models from multiple sources. The ultimate goal is to improve the design of drugs with acceptable pharmaceutical qualities and to enhance the drug approval process.

"We are very happy that the FDA has been pleased with the results of the initial proof of concept work with Bioreason," commented Terry Brunck, Ph.D., Vice President of Research and Development. "The company is excited at the opportunity to expand this into a longer term collaborative relationship."

The ClassPharmer(TM) Suite of software products provides an automated mechanism for learning structure-based classes from screening data that can then be used in a variety of applications. This class-based approach enables the user to easily generate high quality queries and quickly derive conclusions that can be consistently communicated in an intuitive manner throughout the discovery process.

Bioreason, Inc., is headquartered in Santa Fe, New Mexico, with sales and support offices in Strasbourg (France) and Michigan, and with sales and support representation in Tokyo. Bioreason provides knowledge-based software, services, and collaborations that automate reasoning with complex data in the drug discovery process. For information on the company, see http://www.bioreason.com/ .

Bioreason, Inc.

CONTACT: Patricia Bacha, Senior Scientist of Bioreason, Inc.,+1-505-995-8188



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES